Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS Co. Ltd.) was established in 2016 and is a leading global enterprise in the fields of medical imaging AI and medical imaging equipment. The company has seven subsidiaries and branches in countries and regions such as Singapore. The company is led by multiple national-level experts who guide the research and development, production, and sales teams. Over 50% of the R&D team holds a master's degree or higher, with more than 10 years of experience in the medical industry. The company has successively hosted and participated in several national and provincial-level scientific research projects, including special national key R&D programs. It has created the world's largest general medical imaging model, and holds over 60 core independent intellectual property rights in various fields such as prenatal diagnosis, assisted reproduction, hematology and oncology diagnosis, and radiological health across China, the United States, Europe, and other regions.


The company has established Zhejiang Provincial Enterprise R&D Center, Training and Exhibition Center, GMP Production Workshops of Class 100,000 to Class 100, Molding Processing and 3D Printing Workshops, among others. In 2019, it successfully launched the world's first AI-based chromosome intelligent analysis system (AutoVision®) and its high-precision scanning equipment (MetaSight®). In 2023, it received the "First (Set) International Equipment" certification from relevant government departments. Several core medical products have achieved the highest market share.

Customer First
Teamwork
Embrace Change
Quality First
Professionalism and Optimism
Integrity

Diagens

Org chart

Teams

Offices